The Philippine House of Representatives has recently made headlines by voting overwhelmingly in favor of House Bill 10439, a significant bill poised to legalize medical cannabis in the nation. With an astonishing tally of 177 votes in favor, just 9 against, and 9 abstentions, this legislative change marks a pivotal step towards cannabis liberalization in Southeast Asia.
Initially submitted in May 2024, the bill has now been approved at its third and final reading, and is set for its next phase: deliberations in the Senate. If it garners the necessary support there and receives the President’s signature, a structured and comprehensive framework for medical cannabis will emerge, complete with a new regulatory body known as the Medical Cannabis Office (MCO).
Senator Robin Padella, the President of the Partido Demokratiko Pilipino and a long-time advocate for cannabis reform, expressed optimism about the bill’s future. He stated, “The passage of the bill legalizing medical cannabis is very good news. I am hopeful that its counterpart bill in the Senate, the Cannabis Medicalization Act, will also be approved.” His remarks underline the growing momentum towards cannabis liberalization in the Philippines.
What Happens Next?
House Bill 10439, often dubbed the ‘Medical Cannabis Act,’ is now slated for a series of discussions in the Senate. This process will also involve three readings, during which senators will have the opportunity to debate the bill and propose amendments. Following these readings, a reconciliation period between the House and Senate will ensure both chambers reach an agreement on the bill before it can be presented to the President for final approval or veto.
This current bill represents a significant consolidation of previous attempts to legalize medical cannabis in the Philippines. It merges several earlier legislative proposals, including House Bills 241, 243, 2007, and others, into a single, comprehensive initiative. This unification seeks to streamline the legislative process and present a solid front for medical cannabis advocacy in the country.
Key Features of the Medical Cannabis Act
A central tenet of the Medical Cannabis Act is the right for patients to access cannabis as a compassionate medical alternative. It explicitly lists numerous medical conditions that qualify for treatment, such as cancer, glaucoma, multiple sclerosis, epilepsy, HIV, PTSD, and various chronic autoimmune inflammatory disorders requiring hospice care.
The establishment of the Medical Cannabis Office (MCO) will be a cornerstone of the program. Positioned under the Department of Health (DOH), this office will be tasked with regulating all aspects of medical cannabis, from cultivation and manufacturing to distribution and prescription. A critical role of the MCO will include issuing authorizations to accredited physicians who wish to prescribe cannabis. This process requires physicians to receive clearance from the Dangerous Drugs Board (DDB) to ensure they are not on the agency’s watchlist.
Additionally, the MCO will oversee the entire supply chain, including monitoring cannabis from its initial cultivation through to its sale. A sophisticated tracking system is expected to be implemented, enhancing regulatory compliance and ensuring transparency in the medical cannabis market.
Educational Integration
The bill also emphasizes the importance of education, recommending that medical cannabis studies be integrated into university and college curricula. This initiative aims to deepen the understanding of cannabis’ medicinal benefits among future healthcare professionals, thereby promoting informed and safe practices in its use.
Current Context and Future Implications
Despite the ongoing debates in the Senate, the approval of House Bill 10439 signifies a noteworthy shift in the Philippines’ approach to medical cannabis. This development aligns the country with a growing number of nations in Asia, like South Korea and Thailand, that have embraced the medicinal use of cannabis.
The move to legalize medical cannabis comes against a backdrop of existing legislation allowing limited use of CBD for patients with epilepsy, as noted in the ‘Asian Cannabis Report: 2nd Edition’ by Prohibition Partners. However, the high cost associated with current medical cannabis prescriptions, ranging from $25,000 to $30,000 annually, highlights the urgent need for reform.
Advocacy organizations like Sensible Philippines are optimistic about changing perceptions towards cannabis. Kimmi Del Prado, a representative from the organization, commented on the potential impact of legalization, stating, “If done properly, legalization of cannabis in the Philippines will give patients safe access to cannabis-based medicines.” Moreover, emerging trends suggest that public opinion is shifting, with many electoral candidates showing support for medical cannabis legalization.